Teijin Limited and BioVaram, the brand name of the UR Advanced Therapeutics Pvt Ltd. (URAT), signed a business alliance agreement on Nov 13 to explore opportunities for expanding usage of Teijin Group’s implantable medical devices and regenerative medicine products in India, as well as introducing BioVaram’s product portfolio into the Japanese market.
The alliance strives to address unmet medical needs through next-gen MedTech solutions in Japan and India. Under the agreement, Teijin and BioVaram will explore Regulatory approval and commercialization of SYNFOLIUMⓇ, a cardiovascular repair patch by Teijin Medical Technologies Co., Ltd., in India. Teh partnership opens the oportunities for expanding use of Japan Tissue Engineering Co., Ltd.’s regenerative medicine products in India. Japan Tissue Engineering (J-TEC) is part of the Teijin Group.
The strategic commitment will furthur reinforce the development and commercialization of BioVaram technologies in Japan, including exosome-based diagnostics and therapeutics, Extracellular Matrix mimics, and bio-derived materials such as Type I atelocollagen.
Dr.Takayuki Nakano, Mission Executive and General Manager, Regenerative Medicine & Implantable Medical Device Division of Teijin Limited., said “The partnership with UR Advanced Therapeutics marks a highly significant step toward Teijin’s global expansion in the fields of regenerative medicine and implantable medical devices. By combining the exceptional technological capabilities and extensive expertise of both companies across the distinct markets of Japan and India.”
Jaganmohan Reddy, Founder and CEO of UR Advanced Therapeutics, remarked, “This MoU with Teijin Limited marks the beginning of a journey to bring India’s next-generation biotech innovations onto the global stage. It reinforces BioVaram’s vision to build transformative biotech innovations in India together with global partners. This partnership strengthens our capabilities in research, innovation, and scalable manufacturing of advanced tissue engineering products, while enabling Teijin to take BioVaram’s products to global markets."
Moving forward, the two companies will assess business feasibility, regulatory pathways, technical integration, and market needs to advance these initiatives. They will also collaborate on product development and manufacturing in cell and gene therapy, and pursue plans for introducing SYNFOLIUMⓇ in India. By sharing market insights and regulatory information, Teijin and BioVaram aim to build a robust partnership that accelerates innovation in both countries.
